Literature-reported formulation composition
Component: Lipid 10a-26 / Lipid 26 | mol%: 62 | Role: Ionizable lipid
sales@dcchemicals.com
Lipid 10a-26
Literature records
Search the tables and observations reproduced from the product literature guide. Rows may represent measurements, recipes or experimental context; they are not all independent experiments.
Literature-reported formulation composition
Component: DSPC | mol%: 4 | Role: Helper phospholipid
Literature-reported formulation composition
Component: Cholesterol | mol%: 33 | Role: Sterol
Literature-reported formulation composition
Component: DSPE-PEG 2000 | mol%: 1 | Role: PEG lipid
Literature-reported formulation composition
Component: Reported total | mol%: 100 | Role: Source values retained
Reported observation
Literature-reported Whole-body/ex-vivo expression Lipid 26 gave increased total flux and increased overall ex-vivo tissue expression versus Lipids 22-S14 and 93-S14 while retaining the desired spleen:liver expression relationship. FLuc circRNA LNP, IV mouse study · Lipid 22-S14 and Lipid 93-S14 LNPs WO2021189059A2 [0843]-[0844], Fig. 32A-B and Fig. 35A-B.
Reported observation
Literature-reported Splenic immune-cell transfection Lipid 26 LNPs supported circular-RNA expression in multiple splenic immune-cell subsets, including myeloid, B-cell and T-cell populations; the patent reports significantly higher myeloid and T-cell transfection than Lipid 93-S14. Cre circRNA in Ai9 mice · Lipid 93-S14 and PBS background WO2021189059A2 [0861]-[0862], Fig. 45A-C.
Reported observation
Patent synthesis/identity context · WO2021189059A2 [0823]-[0824].